Amylyx Pharmaceuticals Q4 net loss beats estimates

Amylyx Pharmaceuticals

03/03/2026 12:08

Overview

Pharmaceutical firm's Q4 loss per share beat analyst expectations

Net loss for Q4 beat analyst estimates

Company expects cash runway to fund operations through 2028

Outlook

Company expects topline data from Phase 3 LUCIDITY trial in Q3 2026

Amylyx plans potential commercialization of avexitide in 2027

Company targets IND submission for AMX0318 in 2027

Result Drivers

AVEXITIDE DEVELOPMENT - Increased spending on avexitide for PBH offset decrease in R&D expenses

Company press release: ID:nBwbp8fZXa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
Beat
-$0.30
-$0.36 (10 Analysts)
Q4 Net Income
Beat
-$33 mln
-$37.05 mln (9 Analysts)
Q4 Operating Income
Beat
-$36.61 mln
-$40.37 mln (10 Analysts)
Q4 Pretax Profit
Beat
-$32.95 mln
-$39.01 mln (6 Analysts)
Q4 Cash & Investments
$317 mln
Q4 Operating Expenses
$36.61 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $20.00, about 30.7% above its March 2 closing price of $15.30

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)